A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
The purpose of this study is to test whether SU011248 has activity and is safe compared to interferon-alfa as first-line therapy in patients with metastatic renal cell carcinoma (RCC).
Inclusion Criteria:
Exclusion Criteria:
Detoit, Michigan 48201, United States
Victoria, 36184, Australia
Moczowego, Warszawa, Poland
Sutton Surrey, SM2 5PT, United Kingdom